| Source: |
| Type: measurement |
| Bioavailability (usually in %) absorbed by the body. |
| 1638- | HCAs, | Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications |
| - | Review, | Nor, | NA |
| 1643- | HCAs, | Mechanisms involved in the anticancer effects of sinapic acid |
| - | Review, | Var, | NA |
| 2079- | HNK, | Honokiol Microemulsion Causes Stage-Dependent Toxicity Via Dual Roles in Oxidation-Reduction and Apoptosis through FoxO Signaling Pathway |
| - | in-vitro, | Nor, | PC12 |
| 2082- | HNK, | Revealing the role of honokiol in human glioma cells by RNA-seq analysis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 2866- | HNK, | Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship |
| - | Review, | Var, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2886- | HNK, | Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vivo, | NA, | NA |
| 2885- | HNK, | Honokiol: a novel natural agent for cancer prevention and therapy |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 4645- | HT, | Hydroxytyrosol: Bioavailability, toxicity, and clinical applications |
| - | Review, | NA, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 1794- | LEC, | Effects of abomasal infusion of soybean or sunflower lecithin on nutrient digestibility and milk production in lactating dairy cows |
| - | in-vivo, | NA, | NA |
| 1795- | LEC, | Chit, | Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene |
| - | in-vivo, | Nor, | NA |
| 1796- | LEC, | A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin |
| - | Review, | NA, | NA |
| 4292- | LT, | Luteolin for neurodegenerative diseases: a review |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | MS, | NA | - | Review, | Stroke, | NA |
| 2910- | LT, | FA, | Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 2920- | LT, | Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3528- | Lyco, | The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3268- | Lyco, | Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders |
| - | Review, | AD, | NA |
| 3260- | Lyco, | Lycopene in human health |
| - | Review, | NA, | NA |
| 3261- | Lyco, | Lycopene and Vascular Health |
| - | Review, | Stroke, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 1710- | Lyco, | Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases |
| - | Review, | CardioV, | NA |
| 4782- | Lyco, | New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene |
| - | Review, | Var, | NA |
| 4788- | Lyco, | Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review) |
| - | Review, | Var, | NA |
| 4801- | Lyco, | Lycopene in the Prevention of Cardiovascular Diseases |
| - | Review, | CardioV, | NA |
| 4796- | Lyco, | The Anti-proliferation Effects of Lycopene on Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 4792- | Lyco, | A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy |
| - | Review, | Var, | NA |
| 2542- | M-Blu, | In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death |
| - | in-vitro, | Ovarian, | OV1369 | - | in-vitro, | Ovarian, | OV1946 | - | in-vitro, | Nor, | ARPE-19 |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4525- | MAG, | HNK, | Magnolol and Honokiol: Two Natural Compounds with Similar Chemical Structure but Different Physicochemical and Stability Properties |
| - | Study, | Nor, | NA |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 5795- | MET, | Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Diabetic, | NA |
| 2250- | MF, | MNPs, | Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field |
| - | Review, | NA, | NA |
| 3468- | MF, | An integrative review of pulsed electromagnetic field therapy (PEMF) and wound healing |
| - | Review, | NA, | NA |
| 782- | Mg, | Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial |
| - | Trial, | Var, | NA |
| 656- | MNPs, | MF, | Effects of combined delivery of extremely low frequency electromagnetic field and magnetic Fe3O4 nanoparticles on hepatic cell lines |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 2933- | NAD, | Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns |
| - | Review, | Nor, | NA | - | NA, | AD, | NA | - | NA, | Diabetic, | NA | - | NA, | Stroke, | NA | - | NA, | LiverDam, | NA | - | NA, | Park, | NA |
| 2936- | NAD, | The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update |
| 5620- | NaHCO3, | Tumor acidity: From hallmark of cancer to target of treatment |
| - | Review, | Var, | NA |
| 1798- | NarG, | Naringenin: A potential flavonoid phytochemical for cancer therapy |
| - | Review, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:792 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid